Symposia

[1S03m] Drug discovery based on novel therapeutic target to neuropsychiatric disorders in interdisciplinary research

Thu. Jun 30, 2022 9:00 AM - 11:00 AM Room 3 (Conference Building B1 (Okinawa Convention Center))

Chair: Daisuke Ibi, AKIHIRO MOURI

+Add all to schedule

[1S03m-Introduction] Introduction

[1S03m-01] Identification of molecules involved in the pathophysiology of schizophrenia using omics technology and development of biomarkers

*Akira Yoshimi¹ (1. Fac Pharm, Meijo Univ, Nagoya, Japan)

[1S03m-02] PERK dysfunction as a molecular and cellular pathophysiology in the brain of patients with 22q11.2 deletion syndrome and its significance

*Yuko Arioka^1,2 (1. Nagoya Univ Hosp, Aichi, Japan, 2. Dept Psych, Grad Sch Med, Nagoya Univ, Aichi, Japan )

[1S03m-03] Validity of serotonin 5-HT_2A receptor in the lateral septum as a therapeutic target of stress-related disorders

*Daisuke Ibi¹ (1. Dept Chem Pharmacol, Meijo Univ, Nagoya, Japan)

[1S03m-04] Development of biomarker and therapeutic agents for psychiatric disorders focusing on alteration of tryptophan metabolism

*Akihiro Mouri^1,4, Kazuo Kunisawa¹, Kuniaki Saito^2,4, Toshitaka Nabeshima^3,4 (1. Department of Regulatory Science for Evaluation and Development of Pharmaceuticals and Devices, Fujita Health University Graduate School of Health Sciences, 2. Department of Diseases Control and Prevention, Fujita Health University Graduate School of Health Sciences, 3. Advanced Diagnostic System Research Laboratory, Fujita Health University Graduate School of Health Sciences, 4. Japanese Drug Organization of Appropriate Use and Research)

[1S03m-05] Structural biology of GPCRs for drug discovery

*Ryoji Suno¹ (1. Kansai Medical University)

[1S03m-06] Drug Discovery Research in Academia Targeting Orexin Receptors

*Noriki Kutsumura¹ (1. University of Tsukuba)

[1S03m-Closing] Closing Remarks

Session information